ArticleJournal of gynecologic oncology2019
Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma.
Article in Journal of gynecologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Synchronous triple cancers of synchronous endometrial and ovarian carcinoma complicated by renal cancer: a case report.Frontiers in oncology · 2026Article
- Synchronous endometrial/cervical and ovarian/fallopian tube carcinoma: a genome-wide mutation analysis.The journal of pathology. Clinical research · 2025Article
- Homologous recombination deficiency gene panel analysis results in synchronous endometrial and ovarian cancers.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Construction and validation of prognostic nomogram and clinical characteristics for ovarian endometrioid carcinoma: an SEER-based cohort study.Journal of cancer research and clinical oncology · 2023Article
- FIGO staging of endometrial cancer: 2023.Journal of gynecologic oncology · 2023Article
- Endometriosis-Related Ovarian Cancers: Evidence for a Dichotomy in the Histogenesis of the Two Associated Histotypes.Diagnostics (Basel, Switzerland) · 2023Article
- A Presentation of Synchronous Ovarian and Endometrial Endometrioid Adenocarcinoma From a Case of Suspected Ruptured Ectopic Pregnancy.Journal of medical cases · 2023Article
- Case report: Spontaneous remission of synchronous endometrial and ovarian cancers following pregnancy.Frontiers in oncology · 2022Article
- How to manage synchronous endometrial and ovarian cancer patients?BMC cancer · 2021Article
- A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer.Frontiers in oncology · 2021Review
- The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas.Archives of gynecology and obstetrics · 2019Article
- Expression profile and prognostic value of SFN in human ovarian cancer.Bioscience reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGynecologists occasionally encounter synchronous endometrial and ovarian endometrioid carcinoma (SEO-EC) patients who show favorable prognosis than locally advanced or metastatic disease patients. This study aimed to elucidate prognostic factors of SEO-EC and identify patients who have a sufficiently low risk of recurrence without receiving adjuvant chemotherapy.
methodsWe retrospectively reviewed 46 patients with pathologically confirmed SEO-EC who underwent surgery at the National Cancer Center Hospital between 1997 and 2016. Immunohistochemical evaluation of DNA mismatch repair (MMR) protein expression were performed for both endometrial and ovarian tumors. Patient outcomes were analyzed according to clinicopathologic factors.
resultsFrom the multivariate analysis, cervical stromal invasion indicated a worse prognosis for progression-free survival (hazard ratio [HR]=6.85; 95% confidence interval [CI]=1.50-31.1) and overall survival (HR=6.95; 95% CI=1.15-41.8). Lymph node metastasis and peritoneal dissemination did not significantly affect survival. MMR deficiency was observed in 13 patients (28.3%), with both endometrial and ovarian tumors showing the same MMR expression status. MMR deficiency was not significantly associated with survival. Of 23 patients with lesions confined to only the uterine body and adnexa, only 2 had recurrence in the group receiving adjuvant therapy, while none of the 10 patients who did not receive adjuvant therapy had recurrence.
conclusionSEO-EC patients with tumors localized to the uterine body and adnexa lesions had a low risk for recurrence and may not require adjuvant therapy. SEO-EC may have prognostic factors different from those of endometrial and ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.